These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23647712)

  • 1. Safety and effectiveness of insulin detemir in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
    Soewondo P; Mohamed M; Jain AB; Sy RA; Khoo CM
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S10-6. PubMed ID: 23647712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
    Lim-Abrahan MA; Jain AB; Bebakar WM; Seah D; Soewondo P
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S3-9. PubMed ID: 23647715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of insulin aspart in type 2 diabetic patients: results from the ASEAN cohort of the A₁chieve study.
    Bebakar WM; Lim-Abrahan MA; Jain AB; Seah D; Soewondo P
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S17-23. PubMed ID: 23647713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
    Hussein Z; Lim-Abrahan MA; Jain AB; Goh SY; Soewondo P
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P; Kshanti IA; Pramono RB; Langi YA; Dalem-Pemayun TG
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S47-53. PubMed ID: 23647719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
    Soewondo P; Lindarto D; Wibisono S; Renaldi O; Dalem-Pemayun TG
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S41-6. PubMed ID: 23647718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study.
    Belhadj M; Dahaoui A; Jamoussi H; Farouqi A
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S4-14. PubMed ID: 23958571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
    Lim-Abrahan MA; Yu-Gan S; Jain AB; Sobrepena LM; Racho VA
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.
    Latif ZA; Pathan MF; Siddiqui MN; Sobhan MJ; Rahman MM; Ashrafuzzaman SM
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S30-4. PubMed ID: 23647716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes: a sub-analysis of the A₁chieve study.
    Chraibi A; Ajdi F; Belkhadir J; El Ansari N; Marouan F; Farouqi A
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S27-36. PubMed ID: 23958569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P; Pramono RB; Langi YA; Soetedjo NN; Kshanti IA
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S54-9. PubMed ID: 23647720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of insulin aspart with basal insulin is associated with improved glycemic control in Indian patients with uncontrolled type 2 diabetes mellitus: the A1chieve observational study.
    Banerjee S; Maji D; Baruah M
    J Assoc Physicians India; 2013 Jan; 61(1 Suppl):24-7. PubMed ID: 24482984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of insulin analogues in type 2 diabetic patients from Algeria: a sub-analysis of the A₁chieve study.
    Malek R; Arbouche Z; Dahaoui A; Bachaoui M
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S15-26. PubMed ID: 23958568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study.
    Kesavadev J; Joshi SR
    J Assoc Physicians India; 2013 Jan; 61(1 Suppl):28-30. PubMed ID: 24482985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.
    Damci T; Emral R; Svendsen AL; Balkir T; Vora J;
    BMC Endocr Disord; 2014 Jul; 14():61. PubMed ID: 25048824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center.
    Cander S; Dizdar OS; Oz Gul O; Guclu M; Unal OK; Tuncel E; Erturk E; Imamoglu S; Ersoy C
    Prim Care Diabetes; 2014 Oct; 8(3):256-64. PubMed ID: 24522170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF; Dornhorst A; Sreenan S;
    Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.
    Sreenan S; Virkamäki A; Zhang K; Hansen JB;
    Int J Clin Pract; 2008 Dec; 62(12):1971-80. PubMed ID: 19166444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
    Dieuzeide G; Chuang LM; Almaghamsi A; Zilov A; Chen JW; Lavalle-González FJ
    Prim Care Diabetes; 2014 Jul; 8(2):111-7. PubMed ID: 23953707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight change upon once-daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin-naïve individuals with type 2 diabetes: results from the DIET trial.
    Niswender K; Piletic M; Andersen H; Conradsen Hiort L; Hollander P
    Diabetes Obes Metab; 2014 Feb; 16(2):186-92. PubMed ID: 24112375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.